$CPRX

Russo Gregg sold (to issuer) $15K of CPRX

Russo Gregg (Chief HR Officer) sold (to issuer) 476 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 on 2026-07-15.

Original reporting
SEC EDGAR · Russo Gregg
Published Jul 17, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CPRX
Neutral
medium confidence
Mentioned
$CPRX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CPRXNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider activity but does not introduce new company-specific catalysts such as trial results, guidance, financing, or regulatory actions.

02

Market read

Traders may note insider selling, but the transaction size and lack of new fundamentals make it low signal.

03

What to watch

No 10b5-1 plan is stated, but the filing does not provide context for motivation; the post-transaction holding is 0 shares, which can be consistent with planned diversification or compensation mechanics.

Relevance 3/10Novelty 2/10Timing: filed 2026-07-17 after-hours; reflects 2026-07-15 transaction

Background

The filing is a SEC Form 4 insider transaction for Catalyst Pharmaceuticals, Inc. (CPRX).

Company-level read

Ticker impact

$CPRXNeutralMedium confidence
Context

Catalyst Pharmaceuticals insider Russo Gregg sold 476 shares to the issuer at $31.50 on 2026-07-15, leaving 0 shares.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

Form 4 shows a small, single-transaction sale (about $15k) and does not include new operational, financial, or regulatory information.

Market effects

No clear read-across to the biotech sector from a small Form 4 insider sale.

None.

None.

Counterpoint

The sale could be administrative or liquidity-driven (sale to issuer) and may not signal reduced confidence.

Key entities

  • CATALYST PHARMACEUTICALS, INC.

    CPRX, the company whose insider transaction was reported.

  • Russo Gregg

    Chief HR Officer who sold 476 shares to the issuer.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles